Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sciences Ltd. Roivant bought 16,845,010 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Roivant Sciences Stock Up 1.2 %

ROIV stock opened at $11.07 on Thursday. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The company has a market cap of $8.06 billion, a P/E ratio of 1.96 and a beta of 1.27. The business’s fifty day moving average is $11.82 and its 200-day moving average is $11.59.

Wall Street Analyst Weigh In

Several research firms have weighed in on ROIV. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.93.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the business. Gladius Capital Management LP acquired a new position in shares of Roivant Sciences during the third quarter worth about $35,000. US Bancorp DE lifted its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Roivant Sciences during the second quarter worth about $36,000. GAMMA Investing LLC increased its holdings in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth about $53,000. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.